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Abstract 
Para-aortic lymph node recurrence is a rare type of metastasis from colorectal cancer, and 
no treatment has yet been established. Here, we report on a case of isolated para-aortic 
lymph node metastasis from rectosigmoid cancer that showed complete response to 
chemoradiation therapy with capecitabine/oxaliplatin plus bevacizumab. A 58-year-old 
woman underwent high anterior resection for rectosigmoid cancer in 2009. Para-aortic 
lymph node recurrence occurred in 2011. She underwent radiation therapy (50 Gy) and 8 
courses of capecitabine/oxaliplatin plus bevacizumab. Abdominal computed tomography 
and positron emission tomography with 18-fluorodeoxyglucose did not reveal any para-
aortic lymph node recurrence after chemoradiation therapy. Hence, this case was 
interpreted as a complete response. No recurrence was noted 6 months after the complete 
response. Chemoradiation therapy with capecitabine/oxaliplatin plus bevacizumab is likely 
to be effective in treating patients with para-aortic lymph node recurrence. 
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Introduction 
Since the appearance of new anti-cancer drugs and molecular target agents, 
chemotherapeutic treatment of metastatic colorectal cancer (MCRC) has enhanced the 
quality of life for patients and has improved both progression-free survival (PFS) and 
overall survival (OS) [1]. Capecitabine/oxaliplatin (XELOX) is non-inferior to 
fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line chemotherapy for 
patients with MCRC [2]. The addition of bevacizumab to FOLFOX-4 or XELOX 
significantly improved PFS in the first-line treatment of MCRC [3]. 
Para-aortic lymph node recurrence (PALR) is a rare type of MCRC, and no treatment 
has yet been established [4, 5]. Here, we report on a case of PALR from rectosigmoid 
cancer that showed complete response (CR) to chemoradiation therapy with XELOX 
plus bevacizumab. 
Case Report 
A 58-year-old woman underwent high anterior resection for rectosigmoid cancer in 2009. 
Pathological examination showed a moderately differentiated adenocarcinoma perforating the 
visceral peritoneum, with metastatic involvement in 3 of 12 lymph nodes removed (T4 N1). She 
underwent 5 cycles of oral tegafur/uracil plus leucovorin therapy as postoperative adjuvant 
chemotherapy. In 2011, an abdominal computed tomography (CT) scan showed swollen para-aortic 
lymph nodes (fig. 1a, b). Positron emission tomography with 18-fluorodeoxyglucose (FDG-PET)/CT 
fusion imaging indicated FDG accumulations at the right side of the abdominal aorta (fig. 1c). Thus, 
the patient was diagnosed with PALR from rectosigmoid cancer. In May 2011, we started para-aortic 
radiation of 50 Gy in 25 fractions and XELOX plus bevacizumab [oxaliplatin (130 mg/m2) and 
bevacizumab (7.5 mg/kg) on day 1 plus capecitabine (1,000 mg/m2) twice on days 1–14, every 3 
weeks]. After the third course of chemotherapy, the patient experienced G3 neutropenia, and the 
subsequent chemotherapy doses were reduced: capecitabine was reduced by 1 dose level and 
oxaliplatin was reduced to 100 mg/m2. Meanwhile, no dose modification of bevacizumab was 
performed. 
An abdominal CT scan and a FDG-PET/CT scan were performed after the radiation therapy and 8 
cycles of XELOX plus bevacizumab and they did not reveal any PALR (fig. 2). Therefore, the case was 
considered to be a CR. As adjuvant therapy after radiation and XELOX plus bevacizumab, 8 cycles of 
capecitabine [900 mg/body, twice on days 1–14, every 3 weeks] were administered. No sign of 
recurrence or metastasis was noted 6 months after CR was confirmed. 
Discussion 
The introduction of oxaliplatin and irinotecan into combination regimens with 
fluorouracil (5-FU), as well as the development of molecular target agents, has been a 
major advance in the treatment of patients with MCRC. Capecitabine exerts its anti-
cancer effects by generating 5-FU, preferentially through upregulation of thymidine 
phosphorylase (TP) in tumor cells relative to normal cells. Capecitabine generates a 
significantly higher response rate and displays a superior safety profile compared with 
bolus 5-FU/leucovorin [1]. The NO16966 study demonstrated that XELOX was non-
inferior to FOLFOX-4 in terms of PFS, OS, and overall response rate, and the addition of 
bevacizumab to XELOX or FOLFOX-4 significantly improved PFS in the first-line 
treatment of MCRC [3, 4]. The same study showed a longer median OS in the XELOX 
plus bevacizumab arm compared with the XELOX plus placebo arm (21.4 vs. 19.2  
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months, respectively) [4]. The overall rate of grade 3/4 adverse events was similar for 
FOLFOX-4 and XELOX, and the addition of bevacizumab did not alter similarities or 
differences between the safety profile of FOLFOX-4 and XELOX [3]. Since capecitabine is 
given orally and oxaliplatin and bevacizumab are administered every 21 days, XELOX 
plus bevacizumab reduces the need for intravenous drug administration and associated 
visits to the clinic. XELOX plus bevacizumab can be considered as a standard first-line 
treatment for patients with MCRC. 
The common sites of metastasis from colorectal cancer (CRC) are the liver and lung. 
Complete resection of hepatic or lung metastasis results in prolonged survival and 
constitutes a cure in well-selected patients [6]. However, isolated PALR from CRC is 
rarely encountered. Min et al. [4] reported the incidence of PALR to be 1.3% in 2,916 
patients who underwent curative surgery for CRC. Therefore, the treatment for isolated 
PALR from CRC has not been well established. The median survival time after PALR was 
34 months for the patients who underwent surgical resection and 13 months for those 
who underwent radiation therapy (32.4–50.4 Gy) with concurrent or sequential 
chemotherapy or only systemic chemotherapy (p = 0.034) [4]. Although most of the 
patients who were treated in the early 1990s might not receive the benefits of the 
recent developments in chemoradiation treatments, curative resection of PALR might 
achieve long-term survival in selected cases [4]. Kim et al. [5] reported the efficacy of 
stereotactic radiation to treat PALR from CRC. Seven patients with isolated PALR from 
rectal cancer were treated with stereotactic radiation of 36–51 Gy in 3 fractions. The 
study demonstrated that the 1- and 3-year survival rates were 100 and 71.4%, 
respectively, and the median survival time was 37 months. Fujii et al. [7] reported on a 
case where PALR showed CR to oral tegafur/uracil therapy in elderly rectal cancer 
patients. 
Preoperative chemoradiation using bevacizumab, capecitabine, oxaliplatin, and 
standard doses of radiation for patients with high-risk rectal cancer achieved a high 
pathological CR rate [8]. Radiation enhances the expression of TP in tumor tissue [9]. 
The upregulation of TP by radiation may increase preferential delivery of 5-FU to the 
tumor following the administration of capecitabine. 
In conclusion, we report on a case of rectosigmoid cancer with PALR that showed CR 
to chemoradiation therapy with XELOX plus bevacizumab. Chemoradiation therapy 
with XELOX plus bevacizumab is likely to be effective in treating patients with PALR. 
Disclosure Statement 
The authors have no conflicts of interest to declare. 
 
 
 
 
  
Case Rep Oncol 2012;5:216–221 
DOI: 10.1159/000338840 
Published online: 
May 3, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
219 
 
Fig. 1. Imaging before chemoradiation therapy. Abdominal CT scan showed para-aortic lymph node 
swelling (a, b). FDG-PET indicated FDG accumulations at the right side of the abdominal aorta (c). 
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Fig. 2. Imaging after chemoradiation therapy. Abdominal CT scan (a, b) and FDG-PET (c) did not reveal 
any PALR. 
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